ChemoCentryx discovers, develops and commercializes new medicines for inflammatory disorders, cancer, autoimmune and infectious diseases by targeting the chemokine system, the master regulator of immune function. The Company is recognized as a world leader in biology, drug discovery and development based on the chemokine system. ChemoCentryx is developing first-in-class, oral therapies for diseases such as inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis and cancer. ChemoCentryx distinguishes itself through unparalleled chemokine system expertise, innovative technologies and a product-driven approach, which has yielded several exciting drug candidates and the largest pipeline of chemokine-based drugs in the industry.


Date Type Amount Investors Valuation
08/01/06 Series C 17.7M Jennison Associates LLC, HBM Bioventures, OrbiMed Advisors LLC, Techne Corp., Alta Partners, GIMV Unknown
03/01/07 Series D 30M GlaxoSmithKline 188M
09/01/08 Series E 50M Unknown


Markus Cappel (Chief Business Officer)

Juan Jaen (SVP Drug Discovery)

Edward Mocarski (Board Member)

Roger Lucas (Board Member)

Margaret O’Connor (VP Operations)

View more details about all 23 people at ChemoCentryx


MacroGenics: MacroGenics, Inc. is developing immunotherapeutics, including monoclonal antibodies, to treat patients with cancer, autoimmune disorders, allergy,… See Company Profile »
KaloBios Pharmaceuticals: KaloBios has a rapidly growing pipeline of therapeutic antibody drugs directed against a wide variety of… See Company Profile »

View more details about this company's competitors